A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Sheng F Cai, Ying Huang, Jennie R Lance...
https://pubmed.ncbi.nlm.nih.gov/37871309/Actively Recruiting
Led by Beat AML, LLC · Updated on 2026-09-03
3000
Participants Needed
31
Research Sites
N/A
Total Duration
Researchers are investigating a multi-sub-study clinical trial called the Beat AML Master Protocol, focused on biomarker-based treatment for acute myeloid leukemia AML. This Phase 1b23 trial aims to develop a genomic screening method to assign patients to various sub-studies based on the specific AML subtype or other myeloid malignancies. The goal is to evaluate different investigational therapies or combinations to advance targeted treatments for approval. Participants may receive different treatments depending on their assigned sub-study, including investigational drugs like SNDX-5613, venetoclax combined with azacitidine, ZE46-0134, ficlatuzumab, samalizumab, BI 836858, AG-221, entospletinib, pevonedistat, AZD5153, gilteritinib, and others. Treatment schedules vary widely, with dosing cycles ranging from continuous daily oral medications to intravenous infusions on specific days within 28-day cycles. Some studies include dose escalation followed by expansion phases, and treatment may continue until disease progression, unacceptable toxicity, or other protocol-defined criteria. Participants will undergo genomic and biomarker testing to guide treatment assignment within the protocol. They will have regular visits for treatment administration, safety monitoring, disease response evaluation, and laboratory assessments. Outcome measures include the proportion of patients completing biomarker studies within 7 days, assignment to targeted therapies, clinical response rates, event-free survival, overall survival, and quality of life assessments, with follow-up extending up to several years. The trial involves complex monitoring of safety and efficacy to better understand and improve AML treatment options.
CONDITIONS
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
A
Ashley Yocum, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Beat AML, LLC
Lead Sponsor
Syndax Pharmaceuticals
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational biomarker‑guided regimens | Placebo comparator arms |
|---|---|---|
| What this involves | Targets AML treatment based on individual genomic or biomarker findings using investigational drugs in sub‑studies | Includes randomized control arms using placebo maintenance or placebo in regimen components |
| Role in the study | Participants receive experimental targeted therapies matched to their AML subtype | Participants receive placebo instead of maintenance or investigational component in controlled sub‑studies |
| Primary purpose | To evaluate biomarker‑based targeted treatments for AML | Serves as randomized control to assess effect of investigational treatments |
| Administration method | Delivered via intravenous or oral investigational drug regimens, scheduled per biomarker‑assigned sub‑study protocols | Matches investigational administration schedule but uses placebo instead of active drug during maintenance or comparator period |
| Existing clinical evidence | Early-phase precision medicine and biomarker‑matched approaches have shown feasibility and preliminary efficacy in AML | Placebo arms provide internal control but are not established effective treatment |
| Key risks | Safety profile varies by agent and is being evaluated in trial; adverse effects per investigational drugs may occur | Risks arise from background chemotherapy or procedures, placebo itself has no pharmacologic action |
| Limitations | Complex structure with multiple sub‑studies may limit generalizability; treatment effectiveness may vary by biomarker subgroup | Placebo comparison is internal and does not compare against real‑world standard‑of‑care regimens |
| Potential patient impact | Precision‑matched therapies may improve response for specific AML subtypes, though impact remains under study | Placebo arms help determine investigational treatment benefit but do not provide therapeutic benefit |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 7 days
Participants are evaluated for eligibility including genomic testing to determine AML subtype and appropriate sub-study assignment.
1 to 2 visits for testing and consent
Duration - Varies by sub-study and treatment, often several months to years
Participants receive investigational therapies or combinations based on their assigned sub-study, with dosing schedules varying by treatment type and AML subtype.
Regular visits during treatment cycles for administration, monitoring, and assessments
Duration - Up to 5 years or more depending on sub-study
Participants are monitored for treatment response, side effects, and long-term outcomes including survival and quality of life.
Periodic visits for assessments and laboratory tests
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
23
Have more questions? Get in touch with our team for quick support
Sheng F Cai, Ying Huang, Jennie R Lance...
https://pubmed.ncbi.nlm.nih.gov/37871309/Uma M Borate, Ying Huang, Tara L Lin...
https://pubmed.ncbi.nlm.nih.gov/42520193/Hartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum...
https://pubmed.ncbi.nlm.nih.gov/39133932/Joshua F Zeidner, Tara L Lin, Rina Li Welkie...
https://pubmed.ncbi.nlm.nih.gov/40504618/Amy Burd, Ross L Levine, Amy S Ruppert...
https://pubmed.ncbi.nlm.nih.gov/33106665/Uma Borate, Fei Yang, Richard Press...
https://pubmed.ncbi.nlm.nih.gov/37459200/Vu H Duong, Amy S Ruppert, Alice S Mims...
https://pubmed.ncbi.nlm.nih.gov/37078412/Eric D Eisenmann, Ronan Swords, Ying Huang...
https://pubmed.ncbi.nlm.nih.gov/40557912/Antoine N Saliba, Scott H Kaufmann, Eytan M Stein...
https://pubmed.ncbi.nlm.nih.gov/36315007/Len Rosenberg, Hugh Levaux, Ross L Levine...
https://pubmed.ncbi.nlm.nih.gov/33997942/Beat AML, LLC
Lead Sponsor
Syndax Pharmaceuticals
Collaborating Sponsor